RecruitingPhase 2NCT06969027

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

JS207 (PD-1/VEGF Dual Antibody) Combined With Chemotherapy in First-line Treatment of Advanced Non-small Cell Lung Cancer

Sponsor

Shanghai Junshi Bioscience Co., Ltd.

Enrollment

84 participants

Start Date

Jun 19, 2025

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

This study targets patients with in first-line treatment of advanced NSCLC， enrolling 60-84 participants. Patients will receive Arm 1: JS207 (10 mg/kg or 15 mg/kg, IV, D1) + Pemetrexed (500 mg/m2 IV, D1) + a platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1), Q3W, for 4 cycles followed by JS207 (10 mg/kg or 15 mg/kg, IV, D1) + pemetrexed (500 mg/m2 IV, D1), Q3W, until meeting the treatment withdrawal criteria. Arm 2: JS207 (10 mg/kg or 15 mg/kg, IV, D1) + Paclitaxel (175 mg/m2 IV, D1) + a platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1), Q3W, for 4 cycles followed by JS207 (10 mg/kg or 15 mg/kg, IV, D1), Q3W, until meeting the treatment withdrawal criteria.The study aims to assess the safety, tolerability, and preliminary efficacy of JS207 combination therapy.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called JS207 combined with standard chemotherapy as a first-line treatment for people with advanced or metastatic non-small cell lung cancer (NSCLC) that cannot be removed with surgery. **You may be eligible if...** - You are between 18 and 75 years old - You have locally advanced (stage IIIB/IIIC), metastatic, or recurrent NSCLC confirmed by biopsy - You have not yet received treatment for your advanced or metastatic disease - You have at least one measurable tumor on scans - Your general health and organ function are good enough for chemotherapy **You may NOT be eligible if...** - Your lung cancer has a specific EGFR or ALK gene mutation (these patients have other targeted treatments) - You have a small cell or neuroendocrine lung cancer component - You have active, uncontrolled autoimmune disease - You have uncontrolled high blood pressure, active bleeding, or serious wounds - You are pregnant or breastfeeding - You have previously received immunotherapy or anti-VEGF drugs for this cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.